StockStory.org on MSN6h
Why Sarepta Therapeutics (SRPT) Stock Is Nosediving
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...
Sarepta price target lowered to $179 from $210 at BofA
BofA lowered the firm’s price target on Sarepta (SRPT) to $179 from $210 and keeps a Buy rating on the shares. Following the news of the ...
RBC downgrades Sarepta on ‘less bullish’ stance after doctor checks
RBC Capital analyst Brian Abrahams downgraded Sarepta (SRPT) to Sector Perform from Outperform with a price target of $87, down from $161. The ...
A recent gene therapy death shines a light on AAV safety
The death of a 16-year-old boy taking a gene therapy this month dealt a fresh blow to the Duchenne muscular dystrophy ...
BioPharma Dive3h
Cell, gene therapy makers lose a champion at FDA with exit of Peter Marks
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
Investor's Business Daily on MSN3h
Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'
For 13 years, Marks led the FDA's Center for Biologics Evaluation and Research, the department in charge of reviewing and approving vaccines, genetic medicines and cell therapies.Please watch the ...
BioWorld6h
Dissecting the role of neural circuits in mental health
In the brain, molecular information is transmitted between cells through neural circuits. Synapses establish connections between the pathways that run from one area to another, allowing the most ...